ANN ARBOR, MI – TUESDAY, AUGUST 8, 2023 –

Ripple Science, a leading clinical trial technology company focused on improving clinical trial recruitment and retention, announced today that it has appointed Mike Stratton as its Vice President of Business Development.

Mr. Stratton is a senior life sciences executive with over 15 years of experience leading teams in the patient recruitment and retention space. He joins Ripple Science with the goal of commercially advancing the company’s technology platform to accelerate the time it takes to bring discoveries to market by addressing the two biggest problems facing the clinical trial industry, recruitment and retention. As the VP of Business Development, Mike will be responsible for implementing an adoption strategy and system to drive product market share based on industry needs at scale.

“We are excited to welcome Mike to Ripple Science. He brings great experience building best-in-class patient recruitment businesses,” said Peter Falzon, President and CEO of Ripple Science. “I look forward to working closely with Mike to accelerate Ripple’s adoption among tech-enabled sites, CROs, and sponsors.”

Prior to joining Ripple Science, Mr. Stratton spent time at EmVenio Research, and previously spent 10 years at Pharmaceutical Product Development (PPD) and its subsidiary, Accelerated Enrollment Solutions (AES). He has held the positions of Global Head of Patient Recruitment Operations (PPD) and Global Head of Enrollment Operations Finance (AES), and many other positions in his tenure there.

“I’m excited to join the management team at Ripple Science and support the product’s trajectory in the space while ensuring our best-in-class technology continues to solve the most burdensome issues experienced by our customers, sites, and trial participants,” Mr. Stratton said. “Optimizing trial efficiencies and outcomes is Ripple’s specialty and the platform brings a real solution to an industry-wide problem.”

About Ripple Science:
Ripple Science, a clinical trial technology company, is leading the digital transformation in clinical trials with a direct-to-patient software platform that was built by researchers for researchers. Ripple de